Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX)

Historical Holders from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
NRIX on Nasdaq
Shares outstanding
77,143,980
Price per share
$18.97
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
84,776,704
Total reported value
$783,330,709
% of total 13F portfolios
0%
Share change
-3,558,897
Value change
-$36,480,185
Number of holders
171
Price from insider filings
$18.97
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.2% $72,644,381 6,284,116 BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 7.2% +35% $63,580,000 +$15,895,000 5,500,000 +33% Deep Track Capital, LP 31 Mar 2025
FMR LLC 4.1% -62% $38,437,849 -$42,758,996 4,159,940 -53% FMR LLC 31 Oct 2025
Commodore Capital LP 4.9% -4% $34,927,708 -$646,292 3,780,055 -1.8% Commodore Capital LP 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 4.2% $36,861,858 3,188,742 Wellington Management Group LLP 31 Mar 2025
As of 30 Sep 2025, Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 171 institutional shareholders filing 13F forms. They hold 84,776,704 shares. .

Top 25 institutional shareholders own 92% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 12% 8,887,537 -15% 0% $82,120,843
BlackRock, Inc. 8.8% 6,762,586 -0.68% 0% $62,486,295
Deep Track Capital, LP 7.9% 6,057,024 -0.13% 1.6% $55,966,902
VANGUARD GROUP INC 5.8% 4,488,776 +0.52% 0% $41,476,290
BAKER BROS. ADVISORS LP 5% 3,882,125 0% 0.26% $35,870,835
Commodore Capital LP 4.9% 3,780,055 -4.3% 1.7% $34,927,708
Redmile Group, LLC 4.8% 3,678,394 -1.5% 3.3% $33,988,361
Vestal Point Capital, LP 4.5% 3,475,000 +74% 1.5% $32,109,000
Point72 Asset Management, L.P. 3.7% 2,871,497 -22% 0.06% $26,532,636
STATE STREET CORP 3.7% 2,862,387 +13% 0% $26,448,456
Soleus Capital Management, L.P. 3.1% 2,422,833 0% 1.2% $22,386,977
MORGAN STANLEY 2.9% 2,260,746 +4.3% 0% $20,889,301
Kynam Capital Management, LP 2.8% 2,168,605 +85% 1.5% $20,037,910
Pictet Asset Management Holding SA 2.6% 1,980,540 -0.91% 0.02% $18,300,190
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,882,682 +0.04% 0% $17,397,440
Sumitomo Mitsui Trust Group, Inc. 2% 1,557,479 +12% 0.01% $14,391,106
Amova Asset Management Americas, Inc. 2% 1,557,479 +12% 0.14% $14,391,106
MILLENNIUM MANAGEMENT LLC 2% 1,523,959 +64% 0.01% $14,081,381
ARK Investment Management LLC 2% 1,510,404 -4.1% 0.08% $13,956,133
DEUTSCHE BANK AG\ 1.9% 1,438,859 +290% 0% $13,295,057
PERCEPTIVE ADVISORS LLC 1.8% 1,416,149 +29% 0.38% $13,085,217
T. Rowe Price Investment Management, Inc. 1.6% 1,197,415 -52% 0.01% $11,065,000
PRICE T ROWE ASSOCIATES INC /MD/ 1.4% 1,099,093 -64% 0% $10,156,000
Affinity Asset Advisors, LLC 1.3% 967,620 0% 0.83% $8,940,809
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 864,380 +42% 0% $7,986,871

Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 31,528 $597,870 +$167,916 $18.97 3
2025 Q3 84,776,704 $783,330,709 -$36,480,185 $9.24 171
2025 Q2 88,319,847 $1,005,944,844 +$40,932,248 $11.39 161
2025 Q1 84,604,598 $1,005,122,777 +$28,667,924 $11.88 168
2024 Q4 81,104,522 $1,528,053,172 +$225,677,197 $18.84 173
2024 Q3 67,877,304 $1,525,459,447 +$59,100,303 $22.47 170
2024 Q2 64,996,165 $1,356,466,249 +$340,051,233 $20.87 172
2024 Q1 49,045,600 $720,957,554 +$50,639,301 $14.70 138
2023 Q4 46,078,653 $475,525,962 +$17,732,104 $10.32 127
2023 Q3 44,845,094 $352,482,854 +$8,466,362 $7.86 129
2023 Q2 43,637,466 $435,668,849 +$11,852,256 $9.99 124
2023 Q1 42,478,076 $376,567,538 -$3,101,624 $8.88 121
2022 Q4 42,696,157 $468,798,220 +$2,144,188 $10.98 119
2022 Q3 43,069,388 $561,182,776 -$38,324,545 $13.03 114
2022 Q2 44,940,935 $567,552,048 +$55,435,115 $12.67 100
2022 Q1 40,367,078 $565,503,716 -$19,332,926 $14.01 111
2021 Q4 40,421,865 $1,170,057,078 +$25,875,537 $28.95 121
2021 Q3 39,378,816 $1,180,362,633 -$11,970,711 $29.96 110
2021 Q2 39,520,770 $1,048,795,893 -$66,662,023 $26.53 103
2021 Q1 41,346,108 $1,285,407,277 +$254,357,641 $31.09 99
2020 Q4 33,136,833 $1,089,462,176 +$26,868,033 $32.88 67
2020 Q3 31,854,383 $1,111,189,598 +$1,111,189,598 $34.91 64